Telomerase as an Important Target of Androgen Signaling Blockade for Prostate Cancer Treatment

Shuang Liu¹, Yanfeng Qi¹, Yubin Ge², Tamika Duplessis¹, Brian G. Rowan¹, Clement Ip³, Helen Cheng⁶, Paul S. Rennie⁵, Izumi Horikawa⁷, Arthur J. Lustig², Qun Yu⁸, Haitao Zhang³,⁹, and Yan Dong¹,⁹

Abstract

As the mainstay treatment for advanced prostate cancer, androgen deprivation therapy (ADT) targets the action of androgen receptor (AR) by reducing androgen level and/or by using anti-androgen to compete with androgens for binding to AR. Albeit effective in extending survival, ADT is associated with dose-limiting toxicity and the development of castration-resistant prostate cancer (CRPC) after prolonged use. Because CRPC is lethal and incurable, developing effective strategies to enhance the efficacy of ADT and circumvent resistance becomes an urgent task. Continuous AR signaling constitutes one major mechanism underlying the development of CRPC. The present study showed that methylseleninic acid (MSA), an agent that effectively reduces AR abundance, could enhance the cancer-killing efficacy of the anti-androgen bicalutamide in androgen-dependent and CRPC cells. We found that the combination of MSA and bicalutamide produced a robust downregulation of prostate-specific antigen and a recently identified AR target, telomerase, and its catalytic subunit, human telomerase reverse transcriptase. The downregulation of hTERT occurs mainly at the transcriptional level, and reduced AR occupancy of the promoter contributes to downregulation. Furthermore, apoptosis induction by the two agents is significantly mitigated by the restoration of hTERT. Our findings thus indicate that MSA in combination with anti-androgen could represent a viable approach to improve the therapeutic outcome of ADT. Given the critical role of hTERT/telomerase downregulation in mediating the combination effect and the fact that hTERT/telomerase could be measured in blood and urine, hTERT/telomerase could serve as an ideal tumor-specific biomarker to monitor the efficacy of the combination therapy noninvasively. Mol Cancer Ther; 9(7); 2016–25. ©2010 AACR.

Introduction

Telomerase is a ribonucleoprotein enzyme charged with attaching telomeric DNA to the ends of chromosomes and, thus, preventing chromosomes from degradation and end-to-end fusion (1). The role of telomerase in tumorigenesis has been well documented. It is activated in 85% to 90% of malignant tumors, but generally not in normal somatic cells (2). The reactivation of telomerase allows cells to overcome replicative senescence, thereby leading to cellular immortalization and oncogenesis. Inhibition of telomerase has been shown to limit life span, impair cell growth, and suppress the tumorigenic potential of cancer cells of different organs, including prostate (3, 4).

Human telomerase consists of a telomerase RNA component, a telomere reverse transcriptase (hTERT), and telomerase-associated proteins (2). The telomerase RNA component and telomerase-associated proteins are constitutively expressed in cancer and normal cells, irrespective of the presence or absence of telomerase activity. However, a strong correlation has been observed between hTERT mRNA expression and telomerase activity (5, 6).

The expression of hTERT and the activity of telomerase are regulated by androgen receptor (AR) signaling. In LNCaP human prostate cancer cells that express a mutant but functional AR, androgen was shown to induce telomerase activity by recruiting AR to the hTERT promoter and increasing its transcription (7, 8). However, exogenously expressed wild-type AR was shown to inhibit hTERT transcription in an AR-null prostate cancer cell line (8). The data, nonetheless, cannot be generalized to the conclusion that wild-type suppresses hTERT expression. Activated AR is known to inhibit the growth of
AR-null cells, as opposed to the growth-stimulatory effect seen in prostate cancer cells expressing endogenous AR (9). In fact, evidence from both xenograft and human prostate cancer studies have indicated that endogenously expressed wild-type AR positively regulates hTERT expression (7, 10). Castration was shown to decrease hTERT expression and telomerase activity in CWR22 xenograft tumors (7), which express a wild-type AR (11), and these effects were reversed by the subsequent administration of androgen (7). A study of 30 prostate cancer patients underwent androgen deprivation therapy (ADT) before prostatectomy showed that hTERT expression dropped to 36% of pretreatment level as a result of ADT (10). AR genotyping was not done in this study. However, because AR mutations occur at low levels in prostate carcinomas (12), it is reasonable to believe that the majority of the prostate cancer cells in the patients express a wild-type AR. Collectively, the data show a positive regulation of hTERT/telomerase by endogenously expressed AR in prostate tumors, and suppression of AR signaling could represent a viable approach for blocking telomerase activation in the tumor.

Our previous studies showed that methylated forms of selenium are very effective in reducing AR abundance and thereby AR trans-activation (13–16). Selenium is an effective anticancer agent in cancers of various sites, including the prostate, by numerous preclinical studies, epidemiologic observations, and clinical trials (17, 18). Although the interim analysis of the Selenium and Vitamin E Chemoprevention Trial (SELECT) indicated that supplementation of healthy individuals with nutritional dose of selenium did not reduce prostate cancer risk (19), the finding should not have been entirely unexpected. The anticancer efficacy of selenium depends on the form and dosage of selenium administered and the stage of the disease progression (17, 20–23). In fact, animal studies using xenograft models have shown that selenomethionine, the form of selenium used in the SELECT, is ineffective against prostate cancer growth, whereas “second generation” selenium compounds, including methylseleninic acid (MSA), are very effective in inhibiting tumor growth (21, 23). This is in concordance with the fact that selenomethionine is converted to the active metabolite, methylselenol, much less efficiently than the much more potent new selenium compounds (17, 20, 24). Additionally, in most of the preclinical studies that showed a positive association between selenium administration and tumor inhibition, the experiments were conducted by using pharmacologic doses of selenium, not the nutritional dose that was used in the SELECT. Therefore, the negative SELECT finding underscores the urgency of studying the efficacy of the new selenium compounds, particularly at pharmacologic doses, for prostate cancer intervention. Selenium has a low toxicity profile. Although the recommended dietary allowance and the tolerable upper intake level for selenium for adults are set at 55 and 400 μg/d, respectively (25), patients with biopsy-proven prostate cancer supplemented with 3,200 μg selenium per day for an average of 1 year did not develop any serious selenium-related toxicities (26). Therefore, selenium supplementation at pharmacologic doses will be well tolerated.

We have previously reported that treatment of prostate cancer cells with MSA, at a concentration between 2.5 and 10 μmol/L, could markedly decrease the levels of AR mRNA and protein (13, 14). In mice given a nontoxic dose of MSA, serum selenium level reaches a peak level of 12.5 μmol/L at 1 hour and gradually declines to basal level by 24 hours (27). Therefore, the concentrations of MSA that could suppress AR expression are physiologically relevant. We have also found that the reduced abundance of AR results in downregulated AR trans-activation. Ectopic expression of AR reverses MSA suppression of both AR trans-activation and cell growth, suggesting that AR signaling is a key mediator of MSA effect (14). The findings lend credence to the idea that MSA should also be effective in suppressing androgen-induced hTERT expression and telomerase activity. In addition, because MSA and anti-androgen target AR signaling at different levels, through reducing receptor availability and disrupting ligand binding, respectively, combining these two drugs would be expected to produce a more pronounced suppression of AR trans-activation and subsequently hTERT/telomerase, thereby inhibiting the growth/survival of prostate cancer cells. Therefore, the present study was designed to determine the potential of using MSA to increase the efficacy of anti-androgen by characterizing the effects of MSA and an anti-androgen, bicalutamide (Casodex), either alone or in combination, on hTERT expression, telomerase activation, and apoptosis in androgen-dependent and castration-resistant prostate cancer (CRPC) cells.

Materials and Methods

Prostate cancer cell lines and reagents

The LNCaP, 22Rv1, and DU-145 human prostate cancer cell lines were obtained from the American Type Culture Collection at passage 4. Cells used in this study were within 20 passages (~3 mo of noncontinuous culturing). The LAPC-4 cell line (28) was provided by Dr. Charles L. Sawyers at the University of California at Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA. The two castration-resistant LNCaP sublines, LN3 (29) and C81 (30), were obtained from Dr. Curtis A. Pettaway (University of Texas M.D. Anderson Cancer Center, Houston, TX) and Dr. Ming-Fong Lin (University of Nebraska Medical Center, Omaha, NE), respectively. The cells were cultured in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 2 mmol/L glutamine, 100 U/mL of penicillin, and 100 μg/mL of streptomycin. In some experiments, cells were cultured in an androgen-defined condition by using 10% charcoal-stripped FBS in the absence or presence of dihydrotestosterone (DHT). MSA and bicalutamide were purchased from PharmaSe and Toronto Research Chemicals, Inc., respectively.
Apoptosis detection
Detached cells were precipitated by centrifugation and pooled with attached cells. Cytoplasmic histone–associated DNA fragments were quantified by using the Cell Death Detection ELISAPLUS kit (Roche Applied Science) as per the manufacturer’s protocol. The absorbance was measured at 405 nm (reference wavelength at 490 nm) and normalized by the SRB value for cell content.

Quantitative reverse transcription-PCR
The analysis was done as previously described (13) using RNA isolated with the PerfectPure RNA Cultured Cell kit (Fisher Scientific, LLC). The PCR primers and Taqman probes for β-actin (a housekeeping gene), prostate-specific antigen (PSA), and hTERT were products of Applied Biosystems.

Western blot analysis
Details of the procedure for Western blot analysis were previously described (31). Immunoreactive bands were quantitated by volume densitometry and normalized to glyceraldehyde-3-phosphate dehydrogenase. The following antibodies were used in this study (source): anti–glyceraldehyde-3-phosphate dehydrogenase (Millipore), anti-AR (Millipore), and anti-HA (Covance, Inc.).

Telomerase activity assay
Telomerase activity was analyzed by using the TRAPeze Telomerase Detection kit (Millipore) per the manufacturer’s protocol with minor modification. In brief, 2 × 10^5 cells were lysed in 200 μL of CHAPS lysis buffer. Protein concentration of the lysate was determined with the bicinchoninic acid protein assay kit (Pierce), and an amount of 1.5 μg was used in the PCR reaction. The extract was incubated at 30°C for 60 minutes in 50 μL of reaction solution containing the TS primer, reverse primer, deoxynucleotide triphosphates, TRAP reaction buffer (provided by the kit), and Titanium Taq DNA polymerase (Clontech). The products were then subjected to PCR amplification with one cycle at 94°C for 2 minutes and followed by 29 cycles at 94°C for 30 seconds and 59°C for 45 seconds. A pair of internal-control primers was included to monitor the amplification efficiency of each PCR reaction. For each sample, a heat inactivation telomerase control precipitation was done with an AR antibody (PG-21, Millipore) or rabbit IgG (as a negative control) overnight at 4°C. DNA released from the antibody-bound protein/DNA complexes was subjected to regular PCR and quantitated by qRT-PCR.

AR knockdown
LNCaP cells stably transfected with a doxycycline-inducible AR-shRNA lentiviral system was generated as previously described (32). Doxycycline at a concentration of 2 μg/mL was added to the cells 24 hours before the addition of MSA to induce AR knockdown. The MSA treatment continued for 16 hours.

Transient transfection of an hTERT expression vector
The hTERT expression vector, hTERT/pCI-Neo, was purchased from Addgene (# Plasmid 1782). The transfection was carried out in a 10-cm culture dish as previously described (33), and the cells were subsequently trypsinized and replated in triplicate onto a 96-well plate for apoptosis analysis. Cells were allowed to recover for an additional 48 hours before treatment.

Reporter gene assay
The hTERT promoter construct, hTERT-3915/pGL4, was generated by subcloning a ~4-kb (~3,915 to +40) hTERT promoter region from the pBT-3915 plasmid (34) into the pGL4.19 (luc2CP/neo) rapid response luciferase expression vector (Promega). Transfection and luciferase activity analyses were done as previously described (33). To obtain uniform transfection efficiency, transfection was conducted in a 10-cm culture dish, and the cells were subsequently trypsinized and replated in triplicate onto six-well plates for treatments. Luciferase activity was normalized by the protein concentration of the sample.

mRNA stability assay
Actinomycin D (5 μg/mL) was added to the cultures to stop new RNA synthesis at the time of MSA treatment, and hTERT mRNA levels were measured by quantitative reverse transcription-PCR (qRT-PCR) at the 2-, 4-, and 6-hour time points. The turnover of hTERT mRNA was determined by comparing mRNA levels over time in cells treated with or without MSA.

Quantitative nuclear run-on assay
Run-on transcription was done according to a previously described method with biotin-16-UTP (Roche; ref. 35). Biotin-labeled nascent transcripts were then isolated by using streptavidin particle beads and were quantitated by qRT-PCR.

Chromatin immunoprecipitation assay
The chromatin immunoprecipitation (ChIP) assay was carried out by using the ChIP-IT Express kit (Active Motif) per instruction of the manufacturer. Briefly, cells were treated with 1% formaldehyde for 15 minutes at room temperature. Nuclei were isolated, and chromatin was sheared to a size of 500 to 1,500 bp by sonication at 25% power for 10 pulses of 10 seconds each. Immunoprecipitation was done with an AR antibody (PG-21, Millipore) or rabbit IgG (as a negative control) overnight at 4°C. DNA released from the antibody-bound protein/DNA complexes was subjected to regular PCR and quantitative PCR analyses. The sequences of the primers used in regular PCR, −4 kb TERT s and −4 kb TERT as, were as described (8). The sequences of the primers and probes used in the quantitative PCR experiments were as...
follows: hTERT Primer-1, 5′-TCACAGTGAAGAGGACATGCCGT-3′ (−3,844 to −3,820); hTERT Primer-2, 5′-TCAGTATCCCATGGAGGTGGCCAGTTT-3′ (−3,778 to -3,752); and hTERT Probe, 5′/56-FAM/AAGCCTG-CAGGACATCTCAAGGGAATT/3′BHQ_1/3′ (−3,815 to −3,789).

Statistical analysis
Mean activities were calculated from at least three independent experiments done in triplicate. The Student’s two-tailed t test was used to determine significant differences between two groups.

Results

Downregulation of hTERT by androgen-signaling suppression

We first performed dose-response and time course experiments on LNCaP cells cultured in a medium containing charcoal-stripped FBS to study the effect of androgen (in the form of DHT) on the expression of hTERT. Consistent with previous reports (7, 8), DHT treatment of LNCaP cells led to a marked induction of hTERT mRNA (Fig. 1A and B). The induction was dose dependent between 0.1 and 1 nmol/L DHT, and no further increase was observed when DHT was raised to 10 nmol/L (Fig. 1A). Based on this finding, we chose 1 nmol/L DHT for the subsequent experiments. Figure 1B shows the data of the time course experiment. Expression of hTERT mRNA was increased by 2- or 4.5-fold at 16 or 24 hours, respectively. We also examined the effect of DHT on hTERT promoter activity by transiently transfecting LNCaP cells with the hTERT-3915/pGL4 construct, which contains nucleotides −3,915 to +40 of the hTERT promoter region. A significant increase of hTERT promoter activity was detected after treating the cells with DHT for 6 hours. The induction was almost completely blocked by 5 μmol/L bicalutamide, which is an anti-androgen (Fig. 1C). We then studied the consequence of AR knockdown on hTERT expression. As shown in Fig. 1D, the knockdown of AR by treating LNCaP cells stably transfected with a doxycycline-inducible AR-shRNA lentiviral system with doxycycline led to a significant reduction of hTERT mRNA. The data therefore suggest that suppression of AR signaling by either an anti-androgen or AR knockdown could efficiently inhibit hTERT expression.

Downregulation of hTERT/telomerase by MSA

Because MSA reduces AR abundance (13, 14), it would be important to find out whether AR repression by MSA could also lead to hTERT downregulation. We treated LNCaP cells with various concentrations of MSA for 16 hours and determined hTERT mRNA levels by qRT-PCR. As shown in Fig. 2A, as little as 2.5 μmol/L MSA

Figure 1. Androgen-AR regulation of hTERT. A and B, qRT-PCR analysis of hTERT mRNA level in LNCaP cells treated with different doses of DHT for 24 h (A) or 1 nmol/L DHT for 3, 6, 16, or 24 h (B). C, change in hTERT promoter activity, as determined by reporter gene assay, in LNCaP cells as a response to treatment with 1 nmol/L DHT or 1 nmol/L DHT + 5 μmol/L bicalutamide (Bic) for 6 h. D, decrease of hTERT mRNA level, as assessed by qRT-PCR, in response to AR knockdown in LNCaP cells stably transfected with a doxycycline-inducible AR-shRNA. Western blot confirmation of AR protein level is shown in the inset. Data are presented as percentage of ethanol-treated control cells cultured in charcoal-stripped FBS (A–C) or nontreated (no doxycycline) LNCaP cells stably transfected with a doxycycline-inducible AR-shRNA (D). Bars, SEM. *, P < 0.01 compared with control. **, P < 0.01 compared with DHT-treated sample. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
depressed hTERT mRNA level by 40%. Increasing the concentration of MSA to 5 or 10 μmol/L further reduced the level by 80% or more. The downregulation of hTERT mRNA was also time dependent (Fig. 2B). The level of hTERT mRNA declined gradually from 80% of control at 3 hours to 10% of control at 16 hours in response to 10 μmol/L MSA treatment. It is of note that the experiment was done on LNCaP cells cultured in a medium containing regular FBS and treated with MSA for various durations. As shown in Fig. 1B, a 16-hour treatment was required for androgen to induce hTERT mRNA level. The use of regular FBS allowed us to determine the time necessary for MSA to downregulate hTERT in a condition in which AR is already activated.

Similar decreases of hTERT mRNA were also observed in another androgen-dependent cell line, LAPC-4, as well as in three AR-positive castration-resistant cell lines, 22Rv1, C81, and LN3, but not in the AR-negative cell line DU-145 (Fig. 2C). The data shown in Fig. 2C were collected at 3 and 6 hours. We also analyzed hTERT mRNA level in DU-145 cells at 16 and 24 hours, and still could not detect any decrease by MSA (data not shown). Our results thus suggest a universal effect of MSA inhibition of hTERT in AR-positive prostate cancer cells. We wanted to examine the effect of MSA on hTERT protein level. However, none of the three hTERT antibodies we tested (Rockland Immunochemicals for Research, Santa Cruz Biotechnology, and GeneTex) produced a specific signal on Western blots, even with the use of nuclear extracts (see the Supplementary Data). This could be due to the relatively low level of hTERT protein expressed by the cells. To circumvent this problem, we analyzed telomerase activity in response to MSA treatment in LNCaP cells. As shown in Fig. 2D, MSA treatment led to a dose-dependent inhibition of telomerase activity, although the magnitudes of inhibition are smaller than that observed on hTERT transcript level (refer to Fig. 2A for the transcript data). The disparity could be due to different sensitivity of the two assays and/or inherent difference between the extents of effect on hTERT mRNA versus hTERT protein or telomerase activity. Nonetheless, the data collectively showed a marked downregulation of hTERT and telomerase by MSA.

**Inhibition of hTERT transcription by MSA**

To determine whether the MSA downregulation of hTERT was due to increased mRNA degradation or decreased transcription, we performed the mRNA stability assay. Actinomycin D (5 μg/mL) was added to the LNCaP cultures to stop new RNA synthesis at the time of MSA treatment, and hTERT mRNA levels were measured by qRT-PCR during a 6-hour treatment duration. The decay of hTERT mRNA was compared in cells treated with or without MSA. Because actinomycin D could be cytotoxic, we monitored cell growth for up to 8 hours and did not observe cell death or significant growth inhibition during this period. Treatment with 10 μmol/L MSA actually increased the stability of hTERT mRNA (Fig. 3A). We then studied the effect of MSA on hTERT transcription by quantitative nuclear run-on assay. Biotin-labeled nascent transcripts obtained by run-on transcription were isolated by using streptavidin particle beads. To differentiate the effect of MSA on transcription initiation versus transcription elongation, qRT-PCR analysis was conducted with a primer probe set corresponding to either the 5′-end or 3′-end of hTERT mRNA.

**Figure 2.** MSA suppression of hTERT expression and telomerase activity. A, changes in hTERT mRNA, as determined by qRT-PCR, as a function of MSA concentration at 16 h in LNCaP cells. B and C, expression of hTERT mRNA in response to treatment with 10 μmol/L MSA for various durations in LNCaP cells (B) or in LAPC-4, 22Rv1, C81, LN3, and DU-145 cells (C). Data are presented as percentage of nontreated control cells cultured in regular FBS. *, P < 0.01, significantly different from nontreated control. D, TRAP assay of changes in telomerase activity as a function of MSA concentration in LNCaP cells. IC, internal control. The numbers below the gel are normalized telomerase activities relative to nontreated control.
the 3'-end of hTERT mRNA. For both sets of primer probe, MSA treatment resulted in approximately 50% and 80% inhibition of hTERT transcription at 3 and 6 hours, respectively (Fig. 3B). The data thus indicate that the MSA-mediated decrease of hTERT mRNA level is accounted for largely by a block of hTERT transcription initiation. Gene transcription is generally controlled by promoter regions. We next characterized the effect of MSA on the activity of the ~4-kb hTERT promoter in LNCaP cells cultured in a medium containing regular FBS. Treatment with 10 μmol/L MSA caused a time-dependent inhibition of the promoter activity (Fig. 3C). When we repeated the experiment by culturing the cells in charcoal-stripped FBS and adding DHT to the culture, we also found that MSA was able to block DHT induction of hTERT promoter activity (Fig. 3D).

Reduction of AR occupancy of the hTERT promoter by MSA

To show that suppressed hTERT promoter activity is attributable to reduced AR occupancy of the hTERT promoter as a consequence of MSA downregulation of AR, we performed the ChIP assay on the hTERT promoter region that was reported to associate with AR (8). Figure 4A shows the result of PCR amplification of DNA coimmunoprecipitated with either an AR antibody or IgG using primers specific for the hTERT promoter region. The specificity of the ChIP assay is evident from the difference in band intensity between the AR antibody-immunoprecipitated samples and the IgG-immunoprecipitated samples. In concordance with a previous report (8), AR is only weakly associated with the hTERT promoter in the absence of androgen in LNCaP cells. DHT significantly increased the AR occupancy of the promoter, and the increase was blocked by 10 μmol/L MSA. We then conducted quantitative PCR of the coimmunoprecipitated DNA to quantify the change in AR occupancy of hTERT promoter in response to different treatments. As shown in Fig. 4B, DHT treatment induced a ~6-fold increase of AR occupancy of the promoter, and the increase was completely suppressed by MSA.

**Combinatorial effects of bicalutamide and MSA on PSA and hTERT/telomerase**

Bicalutamide and MSA target AR through two distinct mechanisms. As an anti-androgen, bicalutamide suppresses AR trans-activation by competing with androgens for binding to AR. MSA also disrupts AR signaling mainly through reducing the availability of AR (13, 14). Therefore, it is reasonable to believe that the two drugs in combination would produce a more pronounced effect on AR signaling suppression. We quantified the mRNA level of PSA, a well-characterized AR target, by qRT-PCR in LNCaP and LN3 cell models. As shown in Fig. 5A, incubation of LNCaP cells with DHT for 6 hours led to a 3-fold increase of PSA mRNA compared with the vehicle control. The level was reduced to approximately 1.4- or 1.9-fold of the vehicle control as a result of treatment with 5 μmol/L bicalutamide or 2.5 μmol/L MSA, respectively. Combining bicalutamide and MSA at these concentrations brought down DHT-induced PSA expression to ~70% of the vehicle control. We chose to use low doses of bicalutamide or MSA individually to leave room for an enhanced effect with the
Combination. Consistent with the castration-resistant characteristics of LN3 cells, only a marginal induction of PSA mRNA by DHT was observed (Fig. 5A). Treating LN3 cells with 10 μmol/L bicalutamide or 5 μmol/L MSA reduced DHT-induced PSA level to approximately 60% and 50% of the vehicle control, respectively. The combination, on the other hand, almost completely blocked the expression of PSA mRNA. The data thus show a robust suppression of AR trans-activation by bicalutamide and MSA in androgen-dependent and CRPC cells.

We proceeded to evaluate the effect of bicalutamide in combination with MSA on hTERT expression and telomerase activity. The hTERT mRNA data (Fig. 5B) essentially mirror the PSA mRNA result. In LNCaP and LN3 cells, treatment with bicalutamide or MSA alone inhibited DHT-induced hTERT expression; the inhibitory effect was much more striking when the drugs were used in combination. We then analyzed telomerase activity as a result of the combination treatment in the two cell lines. As shown in Fig. 5C, telomerase activity in LNCaP cells was markedly induced by DHT. Bicalutamide or MSA alone produced minimal inhibition of DHT-induced telomerase activity. The two drugs in combination, however, almost completely blocked the DHT induction of telomerase activity. Comparing to the data presented in Fig. 2D, the effect of MSA alone seems to be smaller here (0% versus 19% inhibition). This could be due to the different culturing conditions that were used for the two experiments (charcoal-stripped FBS for Fig. 5C versus regular FBS for Fig. 2D). The combination effect
on telomerase activity was also manifested in LN3 cells (Fig. 5D). Thus, the telomerase activity data were qualitatively similar to the hTERT mRNA result.

**Combinatorial effects of bicalutamide and MSA on apoptosis**

Given the critical role of hTERT/telomerase in regulating cell survival, we assessed the effect of bicalutamide and MSA on apoptosis induction in the absence or presence of hTERT overexpression. LNCaP and LN3 cells were treated with bicalutamide and/or MSA for 48 hours, and apoptosis was analyzed by using the Cell Death ELISA assay. As shown in Fig. 6A and B, in both cell models, bicalutamide and MSA in combination led to a more striking increase of apoptosis than either agent alone. Conversely, the combination efficacy was not observed in the AR-negative DU-145 cell line (Fig. 6C). In concordance with the previously reported AR-independent activity of MSA in prostate cancer cells (31, 36–39), MSA treatment of DU-145 cells resulted in a marked induction of apoptosis. However, the combination with bicalutamide was not able to lead to further induction of apoptosis.

To delineate the functional significance of hTERT downregulation in mediating the effect of bicalutamide and MSA, we transiently transfected LNCaP cells with an hTERT expression construct and assessed the response of the hTERT-overexpressing cells to the induction of apoptosis. The apoptosis assay was conducted at 24 hours after treatments, and the data are presented in Fig. 6D. An abundant presence of hTERT not only weakened the apoptosis-inducing ability of bicalutamide or MSA alone but also significantly inhibited the apoptosis-inducing efficacy of the combination treatment. One reason that the difference was seemingly compressed was due to the fact that only a fraction of cells was successfully transfectected, and apoptosis was assessed using the whole cell population. It is of importance to point out that, to obtain uniform transfection efficiency, the transfection was carried out in a 10-cm culture dish, and the cells were subsequently trypsinized and replated onto a 96-well plate for apoptosis analysis. Because the cells were allowed to recover for an additional 48 hours before treatment, and transiently transfected plasmid generally could not maintain expression beyond 72 hours after transfection, the apoptosis assay in this experiment was conducted at 24 hours after treatments, not at 48 hours as in Fig. 6A. This could contribute to the difference in the magnitude of apoptosis induction observed in the experiments presented in Fig. 6A and D.

**Discussion**

ADT is the mainstay treatment for advanced prostate cancer (40). However, relapse with CRPC invariably occurs. Because CRPC is lethal and incurable (40), developing effective strategies to enhance the efficacy of ADT and circumvent resistance becomes an urgent task. AR expression and signaling are maintained in CRPC although the tumor is no longer responsive to ADT. Prostate cancer can adapt to androgen deprivation by AR
mutation, AR overexpression, androgen-independent activation of AR, and/or by increasing intratumoral androgens through de novo steroidogenesis (41–43). Xenograft studies have shown that knocking down AR expression by shRNA could delay the progression of prostate cancer to CRPC and suppress the growth of prostate tumor that has already progressed to the castration-resistant state (32, 44). Therefore, rationally designed therapies aimed at diminishing the availability of AR would be helpful not only in enhancing the efficacy of ADT, but also in inhibiting the development of CRPC. In this study, we reported for the first time that MSA, an agent that could effectively reduce AR abundance, has the ability to potentiate the cancer killing efficacy of bicalutamide in androgen-dependent and CRPC cells.

Because bicalutamide and MSA suppress AR signaling at different points, a combination of the two drugs would be expected to deliver a more powerful punch in knocking out AR signal transduction. In support of this notion, our data showed that the combination produced a stronger suppression of PSA and hTERT than either agent alone. We also showed that apoptosis induction by the two agents was mitigated by the restoration of hTERT, thus confirming the critical involvement of hTERT downregulation in mediating the combination effect. The downregulation of hTERT occurred mainly at the transcriptional level, and decreased AR occupancy of the hTERT promoter contributes to the reduction of hTERT transcription. These findings, however, cannot exclude the possibility of the existence of an AR-independent mechanism by which MSA diminishes hTERT expression. This possibility deserves further investigation.

The role of telomerase is generally regarded as maintaining telomere length. However, accumulating evidence has indicated that telomerase may have additional functions in regulating cell growth and survival, and thereby oncogenesis (45). Telomeric DNA repeats are associated with an array of telomere-specific proteins in forming a chromosome-protective cap (45). Functional telomeres switch stochastically between capped and uncapped states (46). Telomerase plays an essential role in telomere recapping. Uncapped telomeres, if left uncorrected too long, are recognized as DNA breaks and will trigger a DNA damage response, leading to cell cycle arrest and/or apoptosis (46). Additionally, the nonhomologous end joining of dysfunctional telomeres may result in telomere-telomere fusions and contribute to genomic instability. In the present study, we show that bicalutamide and MSA induce a marked increase of apoptosis at 48 hours. Telomerase suppression by bicalutamide and MSA is unlikely to result in appreciable telomere shortening within such a short period of time. This is actually confirmed by our experiment (data not shown). Therefore, a mechanism independent of telomere shortening should be considered. It is likely that inhibiting telomerase by bicalutamide and MSA could lead to telomere uncapping, which would then trigger a rapid DNA damage response and lead to cell cycle arrest and apoptosis. Experiments are ongoing to test the hypothesis.

The identification of hTERT/telomerase as an important AR target mediating the bicalutamide/MSA effect has great clinical implications. Telomerase activation has been reported in >90% of prostate cancer samples, but not in normal or benign prostatic hyperplasia tissues (47). Telomerase activation has been well documented to play an essential role in cell survival and oncogenesis, and inhibition of telomerase has been shown to suppress growth and tumorigenic potential of prostate cancer cells (3, 48). Blocking telomerase activation by anti-androgen and MSA through suppressing AR signaling could thus represent an effective and selective treatment modality to target prostate cancer cells. In addition, hTERT/telomerase could be measured in blood and urine (49, 50) and, therefore, could serve as a noninvasive, tumor-specific, functionally relevant molecular biomarker for monitoring the efficacy of the intervention.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Dr. Charles L. Sawyers at the University of California at Los Angeles Jonsson Comprehensive Cancer Center; Dr. Curtis A. Pettaway at the University of Texas M.D. Anderson Cancer Center; and Dr. Ming-Fong Lin at the University of Nebraska Medical Center for the generous gift of the LAPC-4, LNCaP, and C81 cell line, respectively.

Grant Support

Department of Defense Prostate Cancer Training grant no. W81XWH-08-1-0291 (S. Liu) and New Investigator grant no. W81XWH-05-1-0598 (H. Zhang), the National Cancer Institute grant no. K01CA114252 (Y. Dong), the American Cancer Society grant no. RSG-07-218-01-TBE (Y. Dong), Jilin Provincial Scholarship for Outstanding Scientists from Jilin Province, China (Y. Dong), the Louisiana Cancer Research Consortium Start-up Fund (Y. Dong and H. Zhang), and partial support provided from developmental funds of the Tulane Cancer Center (Y. Dong).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 10/07/2009; revised 04/12/2010; accepted 04/29/2010; published OnlineFirst 06/22/2010.
Molecular Cancer Therapeutics

Telomerase as an Important Target of Androgen Signaling Blockade for Prostate Cancer Treatment

Shuang Liu, Yanfeng Qi, Yubin Ge, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-09-0924

Supplementary Material
Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2010/06/22/1535-7163.MCT-09-0924.DC1

Cited articles
This article cites 49 articles, 29 of which you can access for free at:
http://mct.aacrjournals.org/content/9/7/2016.full#ref-list-1

Citing articles
This article has been cited by 5 HighWire-hosted articles. Access the articles at:
http://mct.aacrjournals.org/content/9/7/2016.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.